STOCKHOLDERS’ EQUITY (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

SUMMARY OF AGGREGATE COMMON STOCK SHARES ISSUED

Nature		Shares
Shares issued in connection with stock-based compensation			826,193
Sales of common stock pursuant to the ATM Agreement			7,627,566	(*)
Sales of common stock pursuant to the Registered Direct Offering			2,500,000
Total			10,953,759

(*)	7,627,566 shares of common stock were sold pursuant to the ATM Agreement for aggregate proceeds of $41.7 million, gross of commissions and fees.

SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL

		December 31, 2025				December 31, 2024
Expected volatility			84.01% - 84.01	%			90.41% – 136.11	%
Risk-free interest rate			4.20% - 4.20	%			3.78% – 4.79	%
Stock price on date of grant		$	6.97			$	31.28
Dividend yield			0	%			0.00	%
Expected term			1 - 1 Years				1-5 years

SCHEDULE OF COMMON STOCK OUTSTANDING

Changes in common stock options for the years ended December 31, 2025, and 2024 were as follows:

		Number of Options Outstanding and Vested				Weighted Average Exercise Price				Remaining Contractual Life (Years)				Aggregated Intrinsic Value
Outstanding and vested, January 1, 2025			40,667				0.2041				3.44				249,122
Issued (1)			439,996				0.0077
Exercised (2)			(409,996	)			0.0075
Expired			-				-
Forfeited			-				-
Cancelled			-				-
Outstanding and vested, December 31, 2025			70,667				0.1217				4.10				290,321

		Number of Options Outstanding and Vested				Weighted Average Exercise Price				Remaining Contractual Life (Years)				Aggregated Intrinsic Value
Outstanding and vested, January 1, 2024			50,667			$	15.9474				2.40			$	776,864
Issued (3)			429,996				0.0077
Exercised (4)			(399,996	)			0.0075
Expired			-				-
Forfeited			-				-
Cancelled			(40,000	)			20.0000
Outstanding and vested, December 31, 2024			40,667			$	0.2041				3.44			$	249,122

1)	In the year ended December 31, 2025, 439,996 common stock options were issued with a grant date fair value of $ 3,066,772.

2)	In the year ended December 31, 2025, common stock option holders exercised a total 409,996 options at a weighted average exercise price of $0,0075 to purchase our common stock. The exercises were paid for with $3,116 in cash proceeds to us. As a result of the options exercised, we issued 409,996 shares of common stock.

3)	In the year ended December 31, 2024, 429,996 common stock options were issued with a grant date fair value of $13,410,147.

4)	In the year ended December 31, 2024, common stock option holders exercised a total 399,996 options at a weighted average exercise price of $0,0075 to purchase 399,996 shares of our common stock. The exercises were paid for with $2,999 in cash proceeds to us. As a result of the options exercised, we issued 399,996 shares of common stock.

SCHEDULE OF WARRANT ASSUMPTION

SCHEDULE OF WARRANT ASSUMPTION

		December 31, 2025
Expected volatility			85.43% - 85.43	%
Risk-free interest rate			4.20% - 4.20	%
Stock price on date of grant		$	6.45 - 6.45
Dividend yield			0% - 0	%
Expected term			1.99 - 1.99 Years

SCHEDULE OF WARRANT ACTIVITY

Changes in common stock purchase warrants for the years ended December 31, 2025, and 2024 were as follows:

		Number of Options Outstanding and Vested				Weighted Average Exercise Price				Remaining Contractual Life (Years)				Aggregated Intrinsic Value
Outstanding and vested, January 1, 2025			16,668			$	10.4999				-			$	-
Issued			75,000				8.1250
Exercised (1)			-				-
Expired (2)			(16,668	)			10.4999
Forfeited			-				-
Cancelled			-				-
Outstanding and vested, December 31, 2025			75,000			$	8.1250				2.08			$	-

		Number of Options Outstanding and Vested				Weighted Average Exercise Price				Remaining Contractual Life (Years)				Aggregated Intrinsic Value
Outstanding and vested, January 1, 2024			55,761			$	10.6087				1.34			$	1,152,654
Warrants Issued			-				-
Warrants Exercised (3)			(6,667	)			7.5000
Warrants Expired (4)			(25,715	)			8.0556
Warrants Forfeited			-				-
Warrants Cancelled (4)			(6,711	)			23.7500
Outstanding and vested, December 31, 2024			16,668			$	10.4999				0.79			$	-

1)	During the twelve months ended December 31, 2025, warrant holders exercised a total nil warrants to purchase nill shares of our common stock.
2)	During the twelve months ended December 31, 2025, 16,668 warrants expired.
3)	During the twelve months ended December 31, 2024, warrant holders exercised a total 6,667 warrants to purchase 1,376 shares of our common stock. The warrant exercises were executed with an exercise price of $7.50 per share and were paid for with 5,291 warrants conceded in cashless exercises. As a result of the warrants exercised, we issued an aggregate of 1,376 common shares.
4)	During the twelve months ended December 31, 2024, 32,426 warrants were canceled and expired.

SCHEDULE OF CHANGE IN RESTRICTED STOCK UNITS

Changes in RSUs for the years ended December 31, 2025, and December 31, 2024 were as follows:

		Number of RSUs Outstanding
Outstanding at January 1, 2025			572,476
Granted (1)			55,750
Vested (2)			(82,000	)
Forfeited (3)			(13,750	)
Cancelled (4)			(338,476	)
Outstanding at December 31, 2025			194,000

		Number of Options Outstanding and Vested
Outstanding January 1, 2024			1,040,017
Granted (1)			714,032
Vested (2)			(749,864	)
Expired			-
Forfeited (3)			(371,709	)
Cancelled (4)			(60,000	)
Outstanding December 31, 2024			572,476

1)	In the twelve months ended December 31, 2025, 55,750 RSUs were granted to our officers and consultants, with a total grant date fair value of $287,008 as measured at $5.15/share, as follows: (i) 5,750 RSUs which immediately vested upon grant and (ii) 50,000 RSUs with time-based vesting over periods ranging from 1 one to four years. In the twelve months ended December 31, 2024, 714,032 RSUs were granted to our officers and consultants , with a total grant date fair value of $7,505,400 as measured at $10.51/share, as follows: (i) 390,997 RSUs which immediately vested upon grant; (ii) 87,326 RSUs with time-based vesting over periods ranging from six months to four years; (iii) 65,000 RSUs which vest upon achieving certain price per share of our common stock ranging between $13.50 and $65.00 and (iv) 170,799 RSUs which vest upon achieving certain performance milestones at our Neves Project
2)	In the twelve months ended December 31, 2025, 82,000 RSUs vested and were settled through the issuance of 82,000 shares of common stock. In the twelve months ended December 31, 2024, 749,864 RSUs vested and were settled through the issuance of 749,864 shares of common stock.
3)	In the twelve months ended December 31, 2025, 13,750 RSUs (371,709 RSUs in 2024) were forfeited upon termination of employment and service agreements with former executives and consultants.
4)	In the twelve months ended December 31, 2025, 338,476 RSUs (60,000 RSUs in 2024) were cancelled without vesting because the performance conditions for vesting were not met.